Time to sputum culture conversion and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis.

Int J Infect DisJun 12, 2026 (epub)
Clinical ResearchInfectious Diseases

Daniel Mulat Eshetu, Thomas Kidanemariam Yewodiaw, Birhanu Feleke Shitu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the time to sputum culture conversion and its predictors among 2851 drug-resistant tuberculosis patients in Ethiopia. The pooled median time to conversion was found to be 68.92 days. The study highlights significant predictors of delayed conversion, including previous anti-tuberculosis treatment and underweight status.

Key findings

  • The pooled median time to sputum culture conversion was 68.92 days (IQR: 57.64-80.19).
  • Previous anti-tuberculosis treatment was associated with delayed conversion (aHR = 0.46; 95% CI: 0.33-0.64).
  • Underweight status was linked to delayed conversion (aHR = 0.75; 95% CI: 0.65-0.84).
  • Lung cavitation was associated with delayed conversion (aHR = 0.48; 95% CI: 0.33-0.69).

Why it matters

Understanding the time to sputum culture conversion and its predictors is crucial for managing drug-resistant tuberculosis. Early identification of at-risk patients can facilitate timely interventions, potentially improving treatment outcomes and reducing transmission.

Source

PubMed · PMID 42285243

Published in Int J Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.